Cardiff Oncology’s PLK1 inhibitorPLK1 inhibitor showed hints of efficacy in a shelved Phase II test in second-line colorectal cancer, boosting Cardiff’s share price ahead of an upcoming readout in the frontline setting.
The deprioritized ONSEMBLE trial studied two doses of the drug candidate, onvansertib, plus standard of care FOLFIRI and Genentech’s Avastin versus standard of care in metastatic colorectal cancer (mCRC) patients with a KRAS or NRAS mutation who had received one prior chemotherapy-based treatment.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.